Total
0
Shares
AusCann Group (ASX:AC8) appoints Nick Woolf as CEO
  • Medicinal cannabis company AusCann Group (AC8) has appointed Nick Woolf as CEO effective immediately
  • Nick will be joining the company after a 25 year stint in the investment banking and life sciences industries, both in Australia and globally
  • Previously, he was Chief Business Officer of Suda Pharmaceuticals (SUD), and Chief Financial Officer of PYC Therapeutics (PYC)
  • After announcing his retirement in early May, previous CEO Ido Kanyon will end his time with AusCann at the end of August, after completing the handover to Nick
  • AusCann is up 5.17 per cent with shares trading for 15.3 cents each

AusCann Group (AC8) has appointed Nick Woolf as CEO effective immediately.

Nick will be joining the company after a 25 year stint in the investment banking and life sciences industries, both in Australia and globally.

Previously, he was CEO of Proteolytics, Chief Business Officer of Suda Pharmaceuticals (SUD), and Chief Financial Officer of PYC Therapeutics (PYC).

"I am excited to be joining AusCann as this pivotal point in its development and building on the work already undertaken by Ido Kanyon in getting our first product into market and commencing our clinical research programs," Nick said.

After announcing his retirement in early May, previous CEO Ido Kanyon will end his time with AusCann at the end of August, after completing the handover to Nick.

Ido joined the company more than 12 months ago from Teva Pharmaceuticals in the United States.

"We would like to thank Ido for his work leading AusCann. During his 17-month tenure with the company he completed the move to the new purpose-built facility, launched our first product into market and commenced our clinical research program," Chairman Max Johnston said.

"He leaves behind a well-qualified team to continue the work commenced during his time," Max said.

AusCann is up 5.17 per cent with shares trading for 15.3 cents each at 12:47 pm AEST.


Subscribe


AC8 by the numbers
More From The Market Herald
Neuren Pharmaceuticals (ASX:NEU) - Outgoing Executive Chairman, Dr Richard Treagus - The Market Herald

" Neuren Pharmaceuticals (ASX:NEU) manufactures NNZ-2951 for phase two trials

Therapy developer Neuren Pharmaceuticals (NEU) has started producing its treatment for an upcoming phase two trial.
Suda Pharmaceuticals (ASX:SUD) - CEO, Dr Michael Baker - The Market Herald

" Suda Pharmaceuticals’ (ASX:SUD) canine trial supports alternative delivery of anagrelide

Suda Pharmaceuticals (SUD) has received the final results from a canine trial of various oral formulations of anagrelide.
Optiscan Imaging (ASX:OIL) - Executive Chairman, Darren Lurie (left) - The Market Herald

" Optiscan Imaging (ASX:OIL) plans $9.8M capital raise

Microscopic imaging company Optiscan Imaging (OIL) is planning a capital raise, with aims to raise up to $9,813,499.
Kazia Therapeutics (ASX:KZA) - CEO & Executive Director, Dr James Garner - The Market Herald

" Kazia Therapeutics (ASX:KZA) partners with DFCI to treat rare lymphoma

Cancer treatment specialist Kazia Therapeutics (KZA) is teaming up with the U.S. Dana-Farber Cancer Institute (DFCI) to treat a rare type of lymphoma.